Treating acute ischemic stroke

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 5, 2008, Pages 626-632

  Fisher, M ^a   Bastan, B ^a  

^a University of Massachusetts   (United States)

Author keywords

Acute ischemic stroke; AIS; Intravenous tissue plasminogen activator; Neuroprotection; t PA

Indexed keywords

ALTEPLASE; DESMOTEPLASE; DISUFENTON SODIUM; HEPARIN; NEUROPROTECTIVE AGENT; PLACEBO; SARUPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; NEUROPROTECTION; RECANALIZATION; REVIEW; TIME;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT DESIGN; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; NEUROPROTECTIVE AGENTS; STROKE; THROMBECTOMY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 50249171785     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP: National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke (2008) 39(3):924- 928. • This study of t-PA use in the US demonstrated that only 1.8 to 2.1% of ischemic stroke patients were treated in 2004.
2. Fisher M, Ratan R: New perspectives on developing acute stroke therapy. Ann Neurol (2003) 53(1):10-20.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med (1995) 333(24):1581-1588.
4. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR et al: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke MOnitoring STudy (SITS-MOST). Lancet (2007) 369(9558):275-282. • The results of t-PA use in clinical practice among 6483 patients at 285 European centers (from 2002 to 2006) demonstrated safety and efficacy in routine clinical practice.
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J Am Med Assoc (1995) 274(13):1017-1025.
6. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (1998) 352(9136): 1245-1251
7. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke. J Am Med Assoc (1999) 282(21):2019-2026.
8. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T et al: Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 363(9411):768-774. •• This important pooled analysis of several t-PA trials demonstrated that very early treatment, within 90 min of stroke onset, was highly efficacious, but treatment between 3 to 4.5 h may offer benefit.
9. Lansberg MG, Thijs VN, Bammer R, Kemp S, Wijman CA, Marks MP, Albers GW: Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke (2007) 38(8):2275-2278. • Data from the DEFUSE study of t-PA use between 3 and 6 h from stroke onset revealed that large diffusion and perfusion MRI lesions are associated with increased hemorrhagic risk.
10. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD: Asymptomatic hemorrhage after thrombolysis may not be benign. Stroke (2007) 38(1):75-79.
11. Duong TQ, Fisher M: Applications of diffusion/perfusion MRI in experimental and clinical aspects of stroke. Curr Atheroscler Rep (2004) 6(4):267-273.
12. Fisher M: The ischemic penumbra: A new opportunity for neuroprotection. Cerebrovasc Dis (2006) 21(Suppl 2):64-70.
13. Butcher KS, Parsons M, MacGregor L, Barber PA, Chalk J, Bladin C, Levi C, Kimber T, Schultz D, Fink J, Tress B et al: Refining the perfusion-diffusion mismatch hypothesis. Stroke (2005) 36(6):1153-1159.
14. Kane I, Carpenter T, Chappell F, Rivers C, Armitage P, Sandercock P, Wardlaw J: Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: Effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. Stroke (2007) 38(12):3158-3164. • Demonstrates that the best approach for defining perfusion MRI lesion volumes has yet to be elucidated.
15. Wintermark M, Reichhart M, Thiran JP, Maeder P, Chalaron M, Schnyder P, Bogousslavsky J, Meuli R: Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol (2002) 51(4):417-432.
16. Ribo M, Molina CA, Rovira A, Quintana M, Delgado P, Montaner J, Grivé E, Arenillas JF, Alvarez-Sabín J: Safety and efficacy of intravenous tissue plasminogen activator in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke (2005) 36(3):602-606.
17. Schellinger PD, Thomalla G, Fiehler J, Köhrmann M, Molina CA, Neumann-Haefelin T, Ribo M, Singer OC, Zaro-Weber O, Sobesky J: MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: An analysis of 1210 patients. Stroke (2007) 38(10):2640-2645. •• This large case series of t-PA-treated patients from German and Spanish centers demonstrated that selection of patients for treatment in the 3- to 6-h time window based upon diffusion/perfusion mismatch identifies a group likely to respond.
18. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB et al: Effects of alteplase beyond 3h after stroke onset in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomized trial. Lancet Neurol (2008) 7(4):299-399. •• An important MRI-based, randomized, placebo-controlled study of t-PA in the 3- to 6-h time window that will serve as the basis for a future phase III pivotal trial.
19. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M et al: The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2005) 36(1):66-73.
20. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 37(5):1227-1231.
21. Forest Laboratories Inc: Topline results of phase III study in acute ischemic stroke (DIAS-2) do not demonstrate difference between desmoteplase and placebo. Press Release (2007) May 31.
22. Warach S: Clinical benefit of desmoteplase treatment in patients with moderate to severe stroke: Further results of the DIAS-2 Trial. International Stroke Conference 2008, New Orleans, LA, USA (2008):LBP2.
23. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F et al: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. PROlyse in Acute Cerebral Thromboembolism. J Am Med Assoc (1999) 282(21):2003-2011.
24. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T: Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke (2007) 38(10):2633-2639.
25. Lisboa RC, Jovanovic BD, Alberts MJ: Analysis of the safety and efficacy on intra-arterial thrombolytic therapy in ischemic stroke. Stroke (2002) 33(12):2866-2871.
26. Lindsberg PJ, Mattle HP: Therapy of basilar artery occlusion: A systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke (2006) 37(3):922-928.
27. Mandava P, Kent TA: Intra-arterial therapies for acute ischemic stroke. Neurology (2007) 68(24):2132-2139. • This thoughtful analysis of case series of patients treated with intraarterial thrombolysis concludes that the studies were highly variable and do not provide evidence that such treatment is beneficial.
28. IMS Study Investigators: Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke (2004) 35(4):904-911.
29. The IMS II Trial Investigators: The Interventional Management of Stroke (IMS) Study. Stroke (2007) 38(7):2127-2135.
30. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE et al: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. Stroke (2005) 36(7):1432-1440. • Presents the data that led to FDA approval of the MERCI device for the removal of intracranial clots. The trial was not randomized and compared this device therapy to historical controls.
31. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP et al: Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke (2008) 39(4):1205-1211.
32. The Penumbra Stroke Trial: Penumbra Inc, Alameda, CA, USA. www.penumbrainc.com/physicians/clinical-trial
33. Lo EH, Moskowitz MA, Jacobs TP: Exciting, radical, suicidal: How brain cells die after stroke. Stroke (2005) 36(2):189-192.
34. Hossmann KA: Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol (2006) 26(7-8):1055-1081. • An excellent review of the pathophysiology of ischemic brain injury.
35. Lo EH: Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol (2008) 153(Suppl):S396-S405.
36. Schäbitz WR, Fisher M: Perspectives on neuroprotective stroke therapy. Biochem Soc Trans (2006) 34(Pt 6):1271-1276.
37. Hussein MS, Shuaib A: Research into neuroprotection must continue but with a different approach. Stroke (2008) 39(2):521-522.
38. Stroke Therapy Academic Industry Roundtable: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 30:2752-2758.
39. Donnan GA: A new road map for neuroprotection. Stroke (2008) 39(2):242-248. •• The continued failure of neuroprotective drugs led to this thoughtful assessment of what steps should be considered in the future to enhance the chances for success with such agents.
40. Phan TG, Donnan GA, Davis SM, Byrnes G: Proof-of-principle phase II MRI studies in stroke: Sample size estimates from dichotomous and continuous data. Stroke (2006) 37(10):2521-2525.
41. Fisher M, Cheung K, Howard G, Warach S: New pathways for evaluating potential acute stroke therapies. Int J Stroke (2006) 1(2):52-58. • Provides suggestions for the design and implementation of future phase II stroke trials.
42. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hårdemark HG, Wasiewski WW: NXY-059 for acute ischemic stroke. N Engl J Med (2006) 354(6):588-600.
43. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 357(6):562-571.
44. Bardutzky J, Meng X, Bouley J, Duong TQ, Ratan R, Fisher M: Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model. J Cereb Blood Flow Metab (2005) 25(8):968- 977.
45. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ: Association between tPA therapy and raised early matrix metaloproteinase-9 in acute stroke. Neurology (2006) 66(10):1550-1555.